See more : L&C Bio Co., Ltd (290650.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Tyme Technologies, Inc. (TYME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyme Technologies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Omphalos, Corp. (OMPS) Income Statement Analysis – Financial Results
- Pyung Hwa Industrial Co., Ltd. (090080.KS) Income Statement Analysis – Financial Results
- Nordic Nanovector ASA (NANOV.OL) Income Statement Analysis – Financial Results
- Niko Semiconductor Co., Ltd. (3317.TWO) Income Statement Analysis – Financial Results
- Panoramic Resources Limited (PANRF) Income Statement Analysis – Financial Results
Tyme Technologies, Inc. (TYME)
About Tyme Technologies, Inc.
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.44M | 17.03M | 12.96M | 14.72M | 8.84M | 6.11M | 3.82M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Other Expenses | 2.44M | 0.00 | 0.00 | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.20K |
| Operating Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | -2.10K |
| Cost & Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | 2.10K |
| Interest Income | 0.00 | 22.08K | 229.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 70.24K | 97.13K | 114.24K | 0.00 | 0.00 | 0.00 | 3.50M | 76.56K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.96M | 5.18K | 5.18K | 8.42K | 4.30K | 4.28K | 4.29K | 76.56K | 0.00 | 0.00 | 0.00 |
| EBITDA | -23.56M | -27.22M | -25.76M | -31.78M | -19.36B | -15.21B | -8.60M | 22.65K | -56.59K | -27.43K | -2.10K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -25.51M | -27.22M | -25.76M | -31.78M | -19.36M | -15.21M | -8.60M | -53.91K | -56.59K | -27.43K | -2.10K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.89M | -1.76M | 3.76M | -1.21M | 19.34B | 15.19B | -3.13M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -23.63M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.96M | -1.66M | 3.87M | -1.21M | 390.39K | 0.00 | 376.26K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -21.67M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
| Weighted Avg Shares Out (Dil) | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
Tyme Technologies Offers Incredible Risk-Reward
Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q2 2021 Results - Earnings Call Transcript
TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference
TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor
TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
Tyme Technologies: The Market Missed The Bullish Memo
Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q1 Fiscal Year 2022 Results - Earnings Call Transcript
TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results
TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET
Source: https://incomestatements.info
Category: Stock Reports